头孢地尔耐药大肠埃希菌临床分离株的病例报告与基因组分析
报告一例肝移植候选者血流感染中碳青霉烯耐药大肠埃希菌对头孢地尔耐药,尽管无该药既往暴露。全基因组测序比较耐药株与敏感相关株,发现多个可能影响头孢地尔作用机制的基因变异,结论认为耐药可能由铁转运体基因cirA突变所致。
要点
- 碳青霉烯耐药大肠埃希菌可在无头孢地尔暴露史时出现头孢地尔耐药。
- 全基因组测序有助于识别头孢地尔耐药相关基因变异。
- cirA基因突变可能是该分离株头孢地尔耐药的原因。
核心结论
- 该大肠埃希菌分离株的头孢地尔耐药可能由铁转运体基因cirA突变所致。
研究设计与样本
- 病例报告:一例肝移植候选者血流感染碳青霉烯耐药大肠埃希菌,该株对头孢地尔耐药且无既往头孢地尔治疗史。
- 采用全基因组测序分析该分离株基因组内容,并与头孢地尔敏感的相关菌株比较基因变异。
主要发现
- 在可能影响头孢地尔作用机制的基因中鉴定出若干变异。
- 该分离株对头孢地尔耐药,尽管无该药既往暴露。
临床怎么用
- 对碳青霉烯耐药革兰阴性菌感染,即使无头孢地尔暴露史也应警惕头孢地尔耐药可能。
- 必要时可通过全基因组测序分析耐药机制,关注cirA等铁转运体基因变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Cefiderocol is a novel siderophore cephalosporin with in vitro activity against multidrug-resistant (MDR), gram-negative bacteria and intrinsic structural stability to all classes of carbapenemases. We sought to identify gene variants that could affect the mechanism of action (MOA) of cefiderocol. METHODS: We report a case of bacteremia in a liver transplant candidate with a strain of carbapenem-resistant Escherichia coli that was found to be resistant to cefiderocol despite no prior treatment with this antimicrobial agent. Using whole-genome sequencing, we characterized the genomic content of this E coli isolate and assessed for genetic variants between related strains that were found to be cefiderocol susceptible. RESULTS: We identified several variants in genes with the potential to affect the mechanism of action of cefiderocol. CONCLUSIONS: The cefiderocol resistance in the E coli isolate identified in this study is likely due to mutations in the cirA gene, an iron transporter gene.
引用
- Price TK, Davar K, Contreras D, et al. Case Report and Genomic Analysis of Cefiderocol-Resistant Escherichia coli Clinical Isolates. Am J Clin Pathol. 2022. PMID: 34542575. doi:10.1093/ajcp/aqab115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。